Published in AIDS Weekly, November 20th, 1995
Under this agreement, Remel has the exclusive rights to manufacture and sell DynaGen's MycoAKT latex agglutination products in the United States and semi-exclusive rights for the rest of the world. The MycoAKT tests are used for the identification of mycobacterial species isolated in culture. DynaGen obtained U.S. Food and Drug Administration (FDA) marketing clearance for its three MycoAKT tests earlier in 1995. Financial terms were not disclosed.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.